Moody's Ratings (Moody's) has completed a periodic review of the ratings of Compass Group Diversified Holdings LLC and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 27 September 2024 in which we reassessed the appropriateness of the ...
Compass Diversified Declares Third Quarter 2024 Distributions on Common and Series A, B and C Preferred Shares WESTPORT, Conn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution of $0.25 per share on the Company’s common shares (the “Common Shares”). The distribution for the three months ended September 30, 2024, is payable on October, 24, 2024, to all holders of record of Common Shares as of October ...
Compass Diversified-Backed Altor Solutions Completes Acquisition of Lifoam Industries WESTPORT, Conn., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) today announced that its subsidiary, Altor Solutions (“Altor”), a leading designer and manufacturer of custom protective and cold-chain packaging solutions for the industrial and life sciences markets, completed its previously announced acquisition of Lifoam Industries, LLC (“Lifoam”), pursuant to the agreement entered into on August 15, 2024. The acquisition was completed for an enterprise value of $137 million (excludi...
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three-month quarter and first nine months of the year that ended September 30, 2024. To access the conference call by phone, use the following and dial-in details will be provided. To access the webcast, use the following . The slides presented during the webcast an...
THOR Industries Announces Fourth Quarter Fiscal 2024 Results Continues Disciplined Approach in Soft Retail Environment 2024 Highlights ($ in thousands, except for per share data) Three Months Ended July 31, Fiscal Years Ended July 31, 2024 2023 Change 2024 2023 ChangeNet Sales$2,534,167 $2,738,066 (7.4)% $10,043,408 $11,121,605 (9.7)%Gross Profit$401,331 $394,305 1.8% $1,451,962 $1,596,353 (9.0)%Gross Profit Margin % 15.8 14.4 +140 bps 14.5 14.4 +10 bpsNet Income Attributable to THOR$90,015 $90,287 (0.3)% $265,308 $374,271 (29.1)%Diluted ...
Two Directors at Compass Diversified Holdings bought 24,800 shares at between 20.155USD and 20.396USD. The significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...
THOR Industries Announces Date for Its Fiscal 2024 Fourth Quarter Earnings Release ELKHART, Ind., Sept. 10, 2024 (GLOBE NEWSWIRE) -- THOR Industries, Inc. (NYSE: THO) today announced that the date for its fiscal 2024 fourth quarter earnings release will be on Tuesday, September 24, 2024, before the market opens. Upon the release of THOR's fiscal 2024 fourth quarter earnings, the Company will concurrently publish a copy of the earnings release, a comprehensive question and answer document and a slide presentation on the Company's website. To view the quarterly earnings documents, please g...
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain. The results of the real-world analysis suggest higher TTFields therapy device usage is significantly associated with improved survival outcomes in a broad population of ndGBM patients. Novocure’s ESMO 2024 Data Presentation Details: Poster #459: Asso...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.